

peer review issues relevant to Council activities.

(Catalog of Federal Domestic Assistance Program No. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; and 93.891, Alcohol Research Center Grants; National Institutes of Health)

Dated: August 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-20770 Filed 8-14-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute on Aging; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Panel: National Institute on Aging Special Emphasis Panel.

Date of Meeting: August 28, 1996.

Times of Meeting: 8:00 a.m. to 3:00 p.m.

Place of Meeting: Gateway Building, Second Floor Conference Room 2C230, 7201 Wisconsin Avenue, Bethesda, MD 20814.

Purpose/Agenda: To review 5 contract proposals.

Contact Person: Arthur D. Schaedel, DVM, Scientific Review Administrator, Gateway Building, Room 2C212, National Institutes of Health, Bethesda, Maryland 20892-9205, (301) 496-9666.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of Panel: National Institute on Aging Special Emphasis Panel.

Dates of Meeting: September 16-17, 1996.

Time of Meeting: September 16—6:30 p.m. to recess; September 17—8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn—Chevy Chase, 5520 Wisconsin Avenue, Bethesda, MD 20815.

Purpose/Agenda: To review a grant application.

Contact Person: Maria Mannarino, M.D., Scientific Review Administrator, Gateway Building, Room 2C212, National Institutes of Health, Bethesda, Maryland 20892-9205, (301) 496-9666.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.866, Aging Research, National Institutes of Health)

Dated: August 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-20774 Filed 8-14-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: August 29, 1996.

Time: 10:30 a.m.

Place: Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Rehana A. Chowdhury, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: August 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-20775 Filed 8-14-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 19, 1996.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4210, (Telephone Conference).

Contact Person: Dr. Bruce Maurer, Scientific Review Administrator, 6701

Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 19, 1996.

Time: 3:15 p.m.

Place: NIH, Rockledge 2, Room 4210 (Telephone Conference).

Contact Person: Dr. Bruce Maurer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 22, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4210 (Telephone Conference).

Contact Person: Dr. Bruce Maurer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

Name of SEP: Biological and Physiological Sciences.

Date: August 27, 1996.

Time: 8:30 a.m.

Place: Sheraton International Hotel, BWI Airport, Baltimore, MD.

Contact Person: Dr. Jerry Roberts, Scientific Review Administrator, 6701 Rockledge Drive, Room 6152, Bethesda, Maryland 20892, (301) 435-1037.

Name of SEP: Behavioral and Neurosciences.

Date: August 29, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 5176 (Telephone Conference).

Contact Person: Dr. Carole Jelsema, Scientific Review Administrator, 6701 Rockledge Drive, Room 5176, Bethesda, Maryland 20892, (301) 435-1248.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-20773 Filed 8-14-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meeting:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: August 15, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4112 (Telephone Conference).

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 12, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-20939 Filed 8-13-96; 1:24 pm]

BILLING CODE 4140-01-M

Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) (NIH) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 61 FR 36737, July 12, 1996), is amended to reflect the reorganization of the Office of the Director, NIH (OD/NIH) (HNA). The reorganization consists of the following: (1) In the Office of the Director (HNA) establish the Office of Program Coordination (HNAN), Office of Community Liaison (HNAP), Office of Legislative Policy and Analysis (HNAQ) (elevated from the Office of Science Policy and Technology Transfer, Office of Legislative Policy and Analysis [HNA67]), and Executive Office (HNAR). (2) In the Office of Disease Prevention (HNA2) establish the Office of Dietary Supplements (HNA25); the Office of Rare Diseases (HNA26) (transferred intact from the Office of

Science Policy and Technology Transfer, Office of Rare Disease Research [HNA6533]); and the Office for Alternative Medicine (HNA27) (transferred intact from the Office of Science Policy and Technology Transfer, Office for Alternative Medicine [HNA6532]). (3) In the Office of Intramural Research (HNA4) establish the Office of Technology Transfer (HNA46) (transferred intact from the Office of Science Policy and Technology Transfer, Office of Technology Transfer [HNA68]); and establish the Office of Loan Repayment and Scholarship (HNA47). (4) Retitle the Office of Science Policy and Technology Transfer (HNA6) to the Office of Science Policy (OSP) (HNA6); elevate and rename the Recombinant DNA Branch (HNA6534) to the Office of Recombinant DNA Activities (HNA69); rename the Office of Strategic Planning and Evaluation (HNA66) to the Office of Science Policy and Operations Research (HNA66); abolish the Science Policy Studies Center (HNA65); and elevate and rename the Science Education Policy Branch (HNA6535) to Office of Science Education (HNA63).

Section HN-B, Organization and Functions, is amended as follows:

(1) Under the heading *Office of the Director (HNA)*, insert the following:

Office of Program Coordination (HNAN). Provides essential support functions for the Office of the Director, including: (1) all Executive Secretariat functions, including correspondence control and tracking; (2) Committee Management functions for all of NIH, which consist of setting policy for all Advisory Committees, Councils, and Boards, providing oversight on reports and other documentation, serving as a liaison with Department committee management staff, and providing technical guidance and information relevant to the operations of advisory bodies; and (3) other primary support functions.

Office of Community Liaison (HNAP).

(1) Advises the Director and the Deputy Director, NIH, on policies, programs, and issues involving the NIH and its community; (2) plans and directs activities to promote collaboration and cooperation between the NIH and its community; (3) conducts and oversees studies, projects, and evaluations designed to address problems, questions, and issues of community concern and environmental impact; (4) ensures that NIH activities that affect the community involve community representation at all levels of design, review, and implementation; and (5) ensures effective communication and collaboration on policy and programs

involving the community between the OD and the operating components of the NIH.

Office of Legislative Policy and Analysis (HNAQ). (1) Advises the NIH Director, Deputy Director, OD staff, and the ICDs on the full range of legislative issues, and provides leadership and direction for NIH legislative analysis, development, and liaison; (2) identifies, analyzes, and reports on legislative developments relevant to NIH programs and activities and the national biomedical research effort; (3) plans and develops new legislative proposals and monitors their progress through the legislative process, including changes in the statutory base of NIH activities; (4) assesses, monitors, and manages the NIH relationship with the NIH Congressional Authorizing and Appropriations Committees and takes necessary action to facilitate improvements in these relationships; (5) provides coordination on NIH legislative matters with the Department, the Congress, Federal Agencies, and other non-Federal national and international organizations; (6) coordinates the preparation of testimony or statements for the OD/NIH before congressional committees or other groups; and (7) develops special reports, staff documents or other studies concerning NIH interests, activities, and relationships.

Executive Office (HNAR). Serves in both a staff and operational capacity for all administrative support activities for the Office of the Director, excluding the Office of Research Services.

(2) Under the heading *Office of Director (HNA)*, *Office of Disease Prevention (HNA2)*, insert the following:

Office of Dietary Supplements (HNA25). (1) Advises the Associate Director for Disease Prevention and provides guidance to the research institutes on research related to the health benefits of dietary supplements and their role in disease prevention; (2) conducts, promotes, and coordinates research at NIH relating to dietary supplements; (3) collects and compiles the results of scientific research relating to dietary supplements; (4) serves as principal advisor to the Secretary, Department of Health and Human Services and the agencies of the Public Health Service on non-regulatory issues relating to dietary supplements; and (5) compiles and maintains a database of scientific research and funding.

Office of Rare Diseases (HNA26). (1) Guides and coordinates NIH-wide activities involving research into combating and treating the broad array of rare diseases (orphan diseases); (2) manages the NIH Rare Diseases and